Qumars Behfar

Dr. Qumars Behfar

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2025 in Clinical and Experimental Medicine
Verified
Journal Article
Open access
AAAlireza Azani
Alireza Azani
MSMalihe Sharafi
Malihe Sharafi
RDReyhaneh Doachi
Reyhaneh Doachi
SASama Akbarzadeh
Sama Akbarzadeh
PLParsa Lorestani
Parsa Lorestani
QBQumars Behfar
Qumars Behfar
Aging is a multifaceted process influenced by many elements. During cell division, the repetitive DNA sequences at the ends of chromosomes called telomeres protect them from degradation. Telomeres shorten alongside each cell division, eventually contributing to cellular senescence and aging. Telomerase as an enzyme has a role in the maintenance of telomere length. Reduced function of telomerase is linked to acceleration of aging and age-related diseases. By affecting cellular function, mutations in particular genes can cause aging. Genes involved in DNA repair, cellular metabolism, and inflammation play the key roles in this process. Accumulated mutations result in cellular dysfunction and age-related diseases over time. Epigenetic changes are the modifications that impact gene expression without altering the DNA sequence. Lifestyle factors (diet, exercise, stress) and environmental influences (toxins, trauma) can cause epigenetic alterations. DNA methylation as well as histone modifications are examples of epigenetic alterations. They influence how cells work and are essential to the aging process. Understanding these molecular mechanisms is essential for developing interventions to promote healthy aging and prevent age-related diseases. This paper explores the potential of CRISPR/Cas9 as a gene-editing tool to target these mechanisms and mitigate age-related conditions, ultimately enhancing longevity and quality of life.

13 December 2025 in Neurotoxicity Research
Verified
Journal Article
Closed access
PDF file
SDSima Dehghani
Sima Dehghani
HKHamidreza Khorsandi
Hamidreza Khorsandi
RHRosa Hosseinzadegan
Rosa Hosseinzadegan
HRHossein Rahimi
Hossein Rahimi
MMMahtab Mottaghi
Mahtab Mottaghi
MGMoein Ghasemi
Moein Ghasemi

28 July 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
AAAlireza Azani
Alireza Azani
NANahal Aghajamal Avval
Nahal Aghajamal Avval
MMMohammad Saeed Soleimani Meigoli
Mohammad Saeed Soleimani Meigoli
MIMahshid Imankhan
Mahshid Imankhan
PAPouya Asgari
Pouya Asgari
MSMalihe Sharafi
Malihe Sharafi
Purpose This review investigates the complex association between type 2 diabetes mellitus (T2DM) and lung cancer, focusing on shared risk factors, molecular mechanisms, and clinical implications. We aim to quantify the impact of T2DM on lung cancer incidence, progression, and treatment response, and evaluate the role of glycemic control and antidiabetic therapies. Methods A narrative review was conducted following a targeted search of PubMed, Scopus, and Web of Science for published studies. Search terms included “type 2 diabetes mellitus,” “lung cancer,” “non-small cell lung cancer,” “hyperglycemia,” “insulin resistance,” and relevant synonyms. Inclusion criteria were original research articles, meta-analyses, and clinical trials involving human subjects that explored epidemiological associations, molecular mechanisms, pharmacologic interventions, or prognostic implications of T2DM in lung cancer. Studies focusing solely on type 1 diabetes, animal models, or non-English language were excluded. Key findings were synthesized to provide mechanistic insights and clinical relevance. Results Epidemiological evidence indicates a 20–48% increased relative risk of lung cancer in individuals with T2DM, with incidence rates reaching 125 per 100,000 in diabetics versus 85 per 100,000 in non-diabetics. Shared risk factors include obesity, smoking, and physical inactivity. Molecular pathways such as K-Ras and PI3K/Akt activation, IGF-1R overexpression, and hyperglycemia-induced oxidative stress promote tumorigenesis and metastasis. Metformin is associated with reduced lung cancer incidence and improved progression-free survival (58% vs. 37% at 2 years). Pioglitazone and DPP4 inhibitors show potential benefits, though clinical evidence remains mixed. Conclusion T2DM significantly influences lung cancer biology and prognosis. Integrating glycemic control with cancer therapy—particularly metformin and EGFR-TKI combinations—offers promising avenues for improving outcomes. Future research should focus on biomarker-driven stratification and targeted therapeutic strategies tailored to diabetic lung cancer patients.

18 July 2025 in Discover Oncology
Verified
Journal Article
Open access
MJMohammadamin Joulani
Mohammadamin Joulani
NANahal Aghajamal
Nahal Aghajamal
MNMasoumeh Nouri
Masoumeh Nouri
FKFaraz Rahmani Khajeh
Faraz Rahmani Khajeh
NSNafiseh Sharifi
Nafiseh Sharifi
QBQumars Behfar
Qumars Behfar
The most common type of cancer and one with a high death rate is lung cancer, especially non-small cell lung cancer (NSCLC), which is mostly brought on by medication resistance, metastasis, and delayed diagnosis. The discovery of non-coding RNAs (ncRNAs), such as circular RNAs (circRNAs), long non-coding RNAs (lncRNAs), and microRNAs (miRNAs), has revealed their vital involvement in the pathophysiology of lung cancer by controlling important cellular processes. The Hippo signaling pathway is one of the critical routes impacted by non-coding RNAs. It is involved in tumor suppression, apoptosis, and cell proliferation. The interaction between ncRNAs and the Hippo pathway in lung cancer is reviewed in this review, with an emphasis on the potential of these molecules as therapeutic targets as well as diagnostic and prognostic biomarkers.

22 April 2025 in Pathology - Research and Practice
Verified
Journal Article
Closed access
SBSoheil Bolandi
Soheil Bolandi
SDSamaneh Dodge
Samaneh Dodge
ZZZahra Zahed
Zahra Zahed
ASAnvar Soleimani
Anvar Soleimani
KMKhaterehsadat Monirvaghefi
Khaterehsadat Monirvaghefi
SDSima Dehghani
Sima Dehghani

1 January 2025 in Journal of Immunology Research
Verified
Journal Article
Open access
MDMona Daghaighei
Mona Daghaighei
SDSamaneh Dodge
Samaneh Dodge
SBSoheil Bolandi
Soheil Bolandi
BYBoutros Youssef
Boutros Youssef
NANiket Attarde
Niket Attarde
AAAlireza Azani
Alireza Azani
Background and Objective: Melanoma is a complex malignancy where the interplay between immune cells, cytokines, and the tumor microenvironment (TME) significantly influences disease progression and patient outcomes. This review explores the involvement of the interleukin‐2 (IL‐2) cytokine family in both the development and therapeutic approaches for melanoma. Methods: A narrative literature review was conducted, synthesizing findings from studies on immune cell behavior, cytokine functions, and their implications in melanoma and other cancers. This narrative review emphasizes the roles of immune cells and cytokines in both promoting and inhibiting tumor growth. Results: Neutrophils, influenced by tumor‐derived cytokines, can adopt phenotypes that either inhibit or promote tumor growth. B cells in the TME often correlate with better survival, although their regulatory forms can suppress immune responses. Tissue‐resident memory T cells (TRM cells) are crucial for antitumor immunity, particularly in response to immune checkpoint inhibitors (ICIs). Dendritic cells (DCs) are vital for antigen presentation, yet their function can be compromised in melanoma. Macrophages frequently support tumor growth through immunosuppressive actions. The IL‐2 cytokine family, including IL‐2, IL‐4, IL‐7, IL‐9, IL‐15, and IL‐21, plays diverse roles in immune regulation. These cytokines are involved in T‐cell proliferation, B‐cell differentiation, and modulation of other immune responses, influencing both tumor progression and the effectiveness of immunotherapies. Conclusions: Immune cells and cytokines are pivotal in the pathogenesis, progression, and immunotherapy of melanoma. Understanding their complex roles offers insights into potential therapeutic strategies, highlighting the importance of targeted immunotherapies in treating melanoma and possibly other cancers. Additional studies are required to clarify the precise mechanisms and interactions occurring within the TME to enhance treatment strategies.